Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of NVP-2203 in Healthy Volunteers
NCT05725252Phase 1Completed
- Sponsor
- NVP Healthcare Co., Ltd.
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NVP-2203-R2 in hypercholesterolemia (2 arms), sponsored by NVP Healthcare Co., Ltd. Primary endpoint: Pharmacokinetics of NVP-2203 in plasma. Started May 2023; status: completed.
02
Drugs
NVP-2203-R2
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05725252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05725252.